Navigation Links
Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Date:11/18/2013

60;

"A favorable trend in overall survival was observed in patients who received talimogene laherparepvec and the trend was pronounced in patients with stage III and IV M1a disease where an important clinical need exists for patients whose disease has not yet spread to distant organs," said Howard Kaufman, M.D., professor and director of the section of surgical oncology in the Department of General Surgery, Rush University Medical Center in Chicago. "I look forward to seeing the final results next year."

Trial Design
This trial was a global, randomized, open-label, Phase 3 trial to evaluate the safety and efficacy of talimogene laherparepvec compared to a control therapy with GM-CSF in over 400 patients with unresected stage IIIB, IIIC or IV melanoma.

Patients were randomized 2:1 to receive either talimogene laherparepvec intralesionally every two weeks or GM-CSF subcutaneously for the first 14 days of each 28 day cycle. Treatment could last for up to 18 months. Where appropriate, stable or responding patients could receive additional treatment on an extension protocol.

About Melanoma
Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, which are the cells responsible for providing pigment to the skin.1 Melanoma is the most aggressive and serious form of skin cancer in which the best treatment approach involves early detection.2 Because it is not always possible to detect cancer in its earlier stage, it can sometimes spread, or metastasize, to other parts of the body.3 The prevalence of metastatic melanoma patients facing recurrence from an earlier stage of disease is predicted to increase by 43 percent by 2015.4 Metastatic melanoma remains a devastating and difficult-to-treat disease with a high unmet need.

Currently, 132,000 melanoma cases occur globally each year.<
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Why did Stephen Hawking become ... so instantly recognizable? Why have they become icons to ... author Hilton Ratcliffe seeks out the answers to those ... to do with science. In " Stephen Hawking Smoked ... 21, 2014), Ratcliffe puts it plainly: , “It ...
(Date:11/21/2014)... 2014 2014 Deep Research Report ... in-depth research report on the transformer market. The ... application, and industry chain structure as well as ... analysis, including China’s domestic market as well as ... situation analysis. The report also covers information on ...
(Date:11/21/2014)... 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. (the ... it has closed a brokered private placement offering ... C$3.7 million.  Cormark Securities Inc. and Clarus Securities ... Offering for a syndicate of agents that also ... (collectively the "Agents"). Concurrently with the Brokered Offering, ...
(Date:11/21/2014)... GUELPH, ON , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... month and nine month periods ended September 30, 2014.  Biorem,s complete ... SEDAR ( www.sedar.com ). Financial Summary:Three-months ended ... CDN$,000 except per share data) , 2014 , ... , 2,282 , 5,281 , 6,715 ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... Last week, the nation marked the five-year anniversary of ... restrictions have unquestionably set back the progress of this ... Congress passed legislation that would have lifted President Bush's ... ones are suffering from a wide range of debilitating ...
... Merge Technologies Inc. , a provider of medical imaging ... said it has received a notice from the staff of ... remains subject to delisting after missing another opportunity to file ... report for the quarter ended June 30 would serve as ...
... The Center for Bioscience and the Integration of Computer ... Gateway Technical College , have come under legal scrutiny for ... complaint filed by the Wisconsin Department of Justice . ... BioCATT could pay a maximum fine of $2,000 each for ...
Cached Biology Technology:Stem cell research holds the promise for tomorrow 2Stem cell research holds the promise for tomorrow 3AG accuses BioCATT of violating meetings law 2
(Date:11/11/2014)... , Nov. 11, 2014  Forensicon, Inc., a ... is pleased to announce the promotion of Yaniv ... of Digital Forensics. In Schiff,s new role as Director, ... team of digital forensics examiners and provide leadership within ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 Schiff ...
(Date:11/6/2014)... from a team of Florida State University biologists could ... adapt to and survive environmental swings such as droughts ... issue of the journal The Plant Cell , ... and proteins) is organized in a cell and how ... turned on and others are turned off. , "If ...
(Date:11/5/2014)... dedicated his career to understanding the Earth,s climate ... , As deputy director and regional climatologist for ... Research Institute, Redmond has more than three decades ... of climate data to the general public. , ... Francisco on December 15-19, 2014 the American Geophysical ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Maize analysis yields whole new world of genetic science 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... 2010: Results from two studies presented today at the ... extracorporeal devices may not confer a survival advantage for ... results among a small sub-group of patients show promise. ... but is valued as a detoxification treatment option for ...
... the International Liver CongressTM 2010 found a link between chronic ... hepatocellular carcinoma. The study found that a higher ... HBV infection in the presence of higher levels of ... effect for HBV infection and if proven to be the ...
... Carbon fixation by phytoplankton in the open ocean plays ... is not fully understood. Until now researchers believed that ... in the open ocean. But now scientists at the ... Southampton have opened ,the black box, of eukaryotic phytoplankton ...
Cached Biology News:'Black box' plankton found to have huge role in ocean carbon fixation 2
... to identify over 150 peptide modifications ... isoforms, protein subsets, and suppress false ... associations and relationships easily. The software ... relative protein expression analysis for discovery ...
... all aspects of classical microscopy in a ... Super Contrast (ASC) objectives coupled with a ... combines flexibility and professional microscopy into one ... the DM-B1 steps into the 21st century ...
... Gene expression profiling allows a high-throuput ... that naturally occuring or artifitially induced changes ... in that system can be detected, studied, ... a broad range of genes at a ...
... agitation and temperature control for microbiology and ... independently and is suitable for DASGIP bioreactors ... volume. Its temperature ranges from approximately 10 ... is equipped with an individual electrical heating ...
Biology Products: